Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GW Pharmaceuticals

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

NICE decision puts NHS in vanguard for new use

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

- PMLiVE

NICE and Canadian counterpart to offer joint advice service

Agencies offer parallel scientific advice

- PMLiVE

UK patient activist group takes aim at Orkambi patent

Calls to bypass patent adds to pressure on Vertex

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Vertex an “extreme outlier” in pricing and behaviour, says NHS England

Members of parliament aim to break three year deadlock

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links